Hortobagyi, Gabriel N.
Article History
First Online: 19 October 2018
Ethics approval
: The MONALEESA-2 trial was conducted in accordance with the Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki.
: Not applicable.
: GNH reports receiving personal fees from Novartis during the conduct of the study, and personal fees from Peregrine Pharmaceuticals, personal fees from Lilly, personal fees from Roche, and personal fees from Agendia outside of the submitted work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.